Related CAS #
17259-75-5 (free base); 27464-23-9 (2HCl)
Synonym
Oxdralazine; DL150; DL-150; DL 150; L6150; L-6150; L 6150
IUPAC/Chemical Name
2,2'-((6-Hydrazino-3-pyridazinyl)imino)diethanol
InChi Key
POFDNYKJHWKGDU-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H15N5O2/c9-10-7-1-2-8(12-11-7)13(3-5-14)4-6-15/h1-2,14-15H,3-6,9H2,(H,10,11)
SMILES Code
NNC1=NN=C(N(CCO)CCO)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
213.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Salvadeo A, Villa G, Segagni S, Piazza W, Criscuolo D. Comparative study of oxdralazine and dihydralazine in essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):372-6. PMID: 7030978.
2: Salvadeo A, Villa G, Segagni S, Galli F, Criscuolo D. A crossover trial of oxdralazine in hypertension. J Clin Pharmacol. 1983 Apr;23(4):155-60. doi: 10.1002/j.1552-4604.1983.tb02719.x. PMID: 6345596.
3: Moskowitz RM, Cohn JN. Hemodynamic effects of oxdralazine and hydralazine in hypertension. Clin Pharmacol Ther. 1980 Jun;27(6):773-8. doi: 10.1038/clpt.1980.109. PMID: 7379444.
4: Salvadeo A, Villa G, Segagni S, Criscuolo D. Long-term study of oxdralazine in hypertensive patients. Arzneimittelforschung. 1979;29(11):1753-5. PMID: 396926.
5: Bartoli E, Faedda R, Arras S, Satta A, Soggia G. Oxdralazine, a new peripheral vasodilator, combined with propranolol and hydrochlorothiazide: a rational approach to antihypertensive treatment. J Clin Pharmacol. 1979 Nov- Dec;19(11-12):751-7. doi: 10.1002/j.1552-4604.1979.tb01647.x. PMID: 536472.
6: de Leeuw PW, van Soest GA, Birkenhäger WH. Aldosterone response to antihypertensive treatment. Clin Exp Hypertens A. 1982;4(9-10):1913-21. doi: 10.3109/10641968209061649. PMID: 6291819.
7: Glorioso S, Romeo B, Borsatti A, Todesco S. Valutazione clinica comparativa dell'efficacia e della tollerabilità del nuovo antiipertensivo DL 150 IT somministrato da solo ed in associazione a reserpina o propranololo [Comparative clinical evaluation of the effectiveness and tolerance of a new antihypertensive agent, DL 150 IT, administered alone and in combination with reserpine or propranolol]. Clin Ter. 1977 Nov 15;83(3):279-99. Italian. PMID: 603983.
8: Kawashima K, Watanabe TX, Sokabe H. Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats. Jpn J Pharmacol. 1980 Feb;30(1):116-8. doi: 10.1254/jjp.30.116. PMID: 6995653.
9: Watanabe TX, Shiono K, Saito K, Sokabe H. Antihypertensive and antidiuretic effects of 3-hydrazino-6-[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) in rats. Jpn J Pharmacol. 1978 Jun;28(3):413-22. doi: 10.1254/jjp.28.413. PMID: 702944.
10: Maseri A, Pesola A, L'Abbate A, Contini C, Magini G. Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150. J Int Med Res. 1976;4(6):402-9. doi: 10.1177/030006057600400605. PMID: 1027634.
